PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody Source: ERS Lung Science Conference 2021 Year: 2021
COVID-19 mRNA vaccines: a step forward from traditional vaccines? Source: Virtual Congress 2021 – Scientific year in review Year: 2021
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017
New concepts in pulmonary oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=63 Year: 2007
Monitoring of monoclonal antibody therapy with a new recovery ELISA assay technique (R-ELISA®) Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
PD-L1 evaluation with DAKO and BIOCARE antibody for immunotherapy; Same coin different faces Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019
Achievements in targeted therapies Source: Eur Respir Monogr 2015; 68: 215-233 Year: 2015
The type II and clara cell specific monoclonal antibody (MMC4) recognises aminopeptidase N Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004
Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011
Novel intradermal influenza vaccine: phase 3 data in targeted adult populations Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Therapeutic strategies: what treatment for what patient Source: Annual Congress 2008 - PG12 - Challenges in pulmonary embolism: hot issues and interactive cases (jointly organised with ACCP) Year: 2008
Targeting IgE: New revelations, new concepts Source: International Congress 2015 – IgE-mediated asthma: New revelations and future insights Year: 2015